- Home
- / ImmunoCellular Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
ImmunoCellular Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.1
2024-10-29
Market Capitalization
$15.9 M
2024-10-29
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|---|---|
| General and administrative expense | 2.4M | 3.6M | 3.4M | 3.2M | 4.6M | 5.0M | 4.0M |
| Operating expense total | 7.4M | 11.3M | 8.7M | 9.2M | 15.5M | 24.1M | 21.2M |
| EBIT | (8.6M) | (11.8M) | (9.5M) | (9.9M) | (24.1M) | (21.2M) | |
| Interest income | 4.3K | 8.6K | 17.3K | 13.9K | 19.9K | 24.4K | 4.7K |
| Pre tax profit | (5.7M) | (14.5M) | (8.8M) | (9.4M) | (12.8M) | (22.1M) | (14.3M) |
| Net Income | (5.7M) | (14.5M) | (8.8M) | (9.4M) | (12.8M) | (22.1M) | (14.3M) |